Up 32% in 2022, Is Eli Lilly Stock Still a Buy?
The consumer price index increased 7.7% year over year in October, a solid signal that the inflation rate is now trending in the right direction. Still, the rate is far above the Federal Reserve's target of 2%.
Due to the long journey that still lies ahead to tame inflation, the S&P 500 index has fallen 16% so far in 2022. But some stocks have fared considerably better than the index to date.
The pharma stock Eli Lilly (NYSE: LLY) is chief among these stocks. Why has the stock surged 33% so far in 2022? And can it continue to outperform the market in the years to come? Let's take a look under the hood at Eli Lilly's fundamentals and valuation to decide.
Source Fool.com
